Sinovac Biotech plans to start a clinical trial of the Chinese vaccine maker’s experimental coronavirus vaccine with children and adolescents in September, widening the company’s test on a shot that is already in the final stage of study with adults.
If you are not happy with the results below please do another search
50 search results for:
Bay Area-based Graphite Bio launched with $45 million in Series A financing and a goal to use gene editing to correct defective genes through high-efficiency site-specific integration of new genetic sequences.
Moderna Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for the treatment of cystic fibrosis (CF).
The U.S. Food and Drug Administration accepted Copenhagen, Denmark-based Orphazyme’s New Drug Application (NDA) for arimoclomol for the treatment of Niemann-Pick disease Type C.
COVID-19 has dramatically altered many of the traditional means of communication and education in the medical community. As often happens in a major crisis, innovations have evolved at lightning speed. Healthcare audience outlooks and expectations have also taken permanent turns.
The adverse events that led to a pause in trials evaluating AstraZeneca Plc’s Covid-19 vaccine candidate may not have been associated with the vaccine itself, according to a document outlining participant information that was posted online by the Oxford University.
San Francisco-based Unity Biotechnology launched a restructuring program to focus on cellular senescence in ophthalmology and neurology.
iBio Inc. is developing a decoy molecule as a therapeutic against SARS-CoV-2.
Hexagon Bio, a California-based biotechnology company turning nature’s DNA into medicines for cancers and infectious diseases with unmet needs, will move into clinical research with $47 million in Series A financing.
The National Institutes of Health (NIH) raised concern about the safety of AstraZeneca’s coronavirus vaccine as the U.S. Food and Drug Administration is weighing whether or not to resume testing in the United States following a global pause in the Phase III trial for safety reasons.